Animal Parasiticides Market By Product Type (Endoparasiticides, Ectoparasiticides, Combination Products), By Animal Type (Companion Animals, Livestock, Poultry), By Formulation (Oral, Topical, Injectable), By Route of Administration (Oral, Topical, Injectable), By End-User (Veterinary Clinics, Animal Farms, Pet Owners, Agricultural Organizations), and By Region; Global Insights & Forecast (2024 – 2030)

As per Intent Market Research, the Animal Parasiticides Market was valued at USD 8.7 billion in 2023 and will surpass USD 15.6 billion by 2030; growing at a CAGR of 8.8% during 2024 - 2030.

The animal parasiticides market is experiencing significant growth due to the increasing global demand for effective solutions to combat parasitic infections in animals. Parasites, including internal (endoparasites) and external (ectoparasites) organisms, pose serious health threats to both companion animals and livestock. This has led to the development of advanced parasiticidal treatments that ensure the well-being of animals and the safety of animal products, such as meat, milk, and eggs. The market is segmented by product type, animal type, formulation, route of administration, and end-user, all of which are driving innovations in the development of new parasiticides. In this overview, we will explore the key sub-segments within each category that are shaping the animal parasiticides market.

Endoparasiticides Segment Is Largest Due to Their Critical Role in Livestock Health

The endoparasiticides segment holds the largest market share due to the critical role these products play in managing internal parasites, such as worms, gastrointestinal parasites, and other protozoan infections that affect livestock and companion animals. Endoparasiticides are vital for the health and productivity of livestock, particularly in animals raised for meat or milk production. Infected animals can experience decreased growth, weight loss, and reduced productivity, all of which have significant economic impacts on the agricultural industry.

The ongoing need to control endoparasitic infections in livestock has driven the continued dominance of this sub-segment. As farmers and veterinary professionals recognize the importance of maintaining parasite-free herds to ensure optimal animal health and productivity, endoparasiticides will remain in high demand. With the growing focus on animal welfare and the prevention of zoonotic diseases, endoparasiticides will continue to be a key product in the animal parasiticide market, driving market growth.

Companion Animals Segment Is Fastest Growing Due to Rising Pet Ownership

The companion animals segment is the fastest growing within the animal type category, driven by the increasing number of pet owners globally and the rising awareness of animal health. Pets, particularly dogs and cats, are highly susceptible to parasitic infections, including ticks, fleas, and internal worms. As pet ownership rises, particularly in urban areas, the demand for effective parasiticidal treatments to protect pets from these health threats has surged.

This segment's rapid growth is also fueled by the increasing focus on preventive healthcare for pets, where regular use of parasiticides is part of maintaining overall pet wellness. Moreover, the availability of a range of safe and effective parasiticides tailored to pets' specific needs has made treatment more accessible. With more people viewing pets as family members and increasing expenditure on pet care, the companion animal parasiticide market is expected to grow rapidly in the coming years.

Oral Formulation Segment Is Largest Due to Convenience and Ease of Administration

The oral formulation segment holds the largest market share within the formulation category due to its ease of use and the convenience it offers both pet owners and veterinary professionals. Oral parasiticides are effective in treating a wide range of parasitic infections, including gastrointestinal worms and heartworms, in both companion animals and livestock. These products are particularly popular among pet owners because they are easy to administer, with minimal discomfort to animals.

The growth of the oral formulation segment is driven by the convenience of dosing animals without the need for professional assistance, which makes it a preferred option for the majority of pet owners and livestock managers. Oral formulations, such as tablets, chews, and liquids, are available in various forms and dosages, making them suitable for different animal types. This versatility, along with the ability to deliver precise doses, contributes to the continued dominance of oral formulations in the parasiticide market.

Oral Route of Administration Is Largest Due to Ease of Use and Effectiveness

In the route of administration segment, the oral route is the largest sub-segment, driven by its simplicity, effectiveness, and convenience. Oral parasiticides are often preferred for both livestock and companion animals as they can be administered directly through food, treats, or in pill form. This route of administration is particularly beneficial for large animals, such as cattle and sheep, as it simplifies mass treatments on farms or agricultural organizations.

For companion animals, oral parasiticides are also a popular choice due to their ease of use at home, allowing pet owners to manage their pets' health without needing a veterinary visit. As the route of administration is directly related to the ease of ensuring proper dosage, oral treatments are often viewed as the most reliable and efficient way to prevent and treat parasitic infections in animals.

Veterinary Clinics End-User Segment Is Largest Due to Expertise and Treatment Access

The veterinary clinics segment is the largest end-user category for animal parasiticides. Veterinary clinics are typically the first point of contact for animal health concerns, including parasitic infections. Veterinarians provide comprehensive care, diagnose parasitic diseases, and recommend appropriate parasiticidal treatments based on the specific needs of the animal. The ongoing growth of veterinary services, particularly in urban areas where pet ownership is rising, contributes to the continued dominance of this segment.

Veterinary clinics play a crucial role in administering parasiticides, especially for companion animals that require professional veterinary guidance for proper diagnosis and treatment. In addition, veterinary clinics are equipped to offer injectable treatments and more specialized parasiticidal therapies that are often necessary for severe or resistant parasitic infections. This expertise, combined with the growing number of clinics in both developed and emerging markets, ensures that veterinary clinics remain the largest end-user segment in the animal parasiticide market.

North America Is Largest Region Due to Advanced Veterinary Care and Pet Ownership

North America holds the largest share of the animal parasiticides market, driven by advanced veterinary care, a high level of pet ownership, and significant expenditure on animal health. The United States, in particular, accounts for a large portion of this market due to the widespread awareness of animal health issues, the popularity of pets, and the strong demand for quality veterinary services. The region's well-established regulatory framework for animal health products also ensures that only safe and effective parasiticides reach the market, driving consumer confidence.

The increasing focus on animal welfare and preventive healthcare in North America is contributing to a higher demand for parasiticidal treatments, particularly in companion animals. Furthermore, the growing adoption of livestock management practices aimed at improving the health and productivity of farm animals continues to bolster the market in this region. North America’s mature healthcare infrastructure for both pets and livestock ensures that the region will maintain its dominant position in the animal parasiticides market.

Leading Companies & Competitive Landscape

The animal parasiticides market is highly competitive, with several key players leading the development and distribution of parasiticidal products. Companies such as Merck Animal Health, Zoetis, Boehringer Ingelheim, Elanco, and Bayer Animal Health are at the forefront of the market, offering a wide range of parasiticides for both livestock and companion animals. These companies have strong research and development capabilities, allowing them to introduce new products that address the evolving needs of animal health.

The competitive landscape is characterized by significant investments in R&D to develop innovative solutions, including new drug formulations, combination products, and novel delivery methods. Additionally, the market is witnessing a growing trend toward combining different active ingredients in single treatments, aiming to target multiple parasitic species simultaneously. As companies continue to focus on expanding their product portfolios and geographical reach, the competition in the animal parasiticide market is expected to intensify, benefiting consumers with more effective and accessible treatment options.

Recent Developments:

• Zoetis Inc. launched a new oral parasiticide for dogs, designed to offer a broad-spectrum solution for controlling both internal and external parasites.
• Bayer AG acquired a leading veterinary parasiticide company, expanding its portfolio in the global animal health market.
• Merck Animal Health received regulatory approval for a new injectable parasiticide aimed at controlling parasitic infections in cattle.
• Elanco Animal Health introduced a combination parasiticide product that targets both internal and external parasites in poultry.
• Boehringer Ingelheim announced a new line of topical parasiticides for companion animals, enhancing its market presence in the pet care sector.

List of Leading Companies:

• Merck Animal Health
• Boehringer Ingelheim
• Elanco Animal Health
• Vetoquinol S.A.
• Ceva Santé Animale
• Heska Corporation
• Virbac
• Dechra Pharmaceuticals
• Bioniche Animal Health
• Intas Pharmaceuticals Ltd.
• Merial (acquired by Boehringer Ingelheim)
• Norbrook Laboratories
• BASF SE
• Woolworths Group
• Xella Group

Report Scope: